Sotac PharmaceuticalsNSE:SOTAC 60 Pretax Margin % is 9.06% as of Sep. 2025, which is 137% above its 10-year median of 3.82. GuruFocus rates NSE:SOTAC with a GF Score™ of 60/100 and a GF Value™ of ₹110.01 (Fairly Valued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Sotac Pharmaceuticals ranks better than 69.46% on this metric.
The historical rank and industry rank for Sotac Pharmaceuticals's Pretax Margin % or its related term are showing as below:
NSE:SOTAC'
s Pretax Margin % Range Over the Past 10 Years
Min: -4.21 Med: 3.82 Max: 14.68
Current: 14.68
NSE:SOTAC's Pretax Margin % is ranked better than 69.46% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.285
vs NSE:SOTAC: 14.68
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Sotac Pharmaceuticals Pretax Margin % Related Terms
Sotac Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SOTAC vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotac Pharmaceuticals (NSE:SOTAC) has a Pretax Margin % of 9.06% as of Sep. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sotac Pharmaceuticals and its competitors. This is 137% above median its historical median of 3.82. According to the industry distribution chart, Sotac Pharmaceuticals ranks #292 out of 956 companies in the Drug Manufacturers industry, placing it in the top 30.5%.
Is Sotac Pharmaceuticals' Pretax Margin % too high?
Sotac Pharmaceuticals' current Pretax Margin % of 9.06% is 137% above median its 10-year median of 3.82. The Drug Manufacturers industry median Pretax Margin % is 7.29. Sotac Pharmaceuticals' value of 9.06% is 24.4% above this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #292 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sotac Pharmaceuticals has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #292 out of 956 companies for Pretax Margin %. This puts Sotac Pharmaceuticals in the upper half of its industry. The industry median Pretax Margin % is 7.29. Sotac Pharmaceuticals' value of 9.06% is 24.4% above this benchmark. While the company's 10-year median is 3.82 vs. the industry median of 7.29, Sotac Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current Pretax Margin % of 9.06% is 24.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current Pretax Margin % is 9.06%, which is 137% above median its own 10-year median of 3.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Fairly Valued. The stock's GF Value™ is ₹110.01, compared to a current price of ₹105.00 — trading 4.6% below its estimated fair value. The current Pretax Margin % is 9.06%, which is 137% above median its 10-year median of 3.82 and 24.4% above the Drug Manufacturers industry median of 7.29. Sotac Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Pretax Margin % is 9.06% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹105.00 is trading 4.6% below its estimated GF Value™ of ₹110.01.
GuruFocus considers Sotac Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:SOTAC:
Pretax Margin %: 9.06% (137% above median its 10-year median of 3.82)
GF Value™: ₹110.01 vs. price of ₹105.00 (4.6% below fair value)
Industry Position: 24.4% above the Drug Manufacturers median (#292 of 956)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
60GF Score
Get the complete analysis for NSE:SOTAC
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
